D. Keith Grossman
Known title: DirectorCIK: 0001218702
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
MiniMed Set for Medtronic Split-Off, Analysts Set New Targets. Medtronic has finalized the exchange ratio for the MiniMed split-off, a key corporate event for the stock. Meanwhile, Mizuho raised its price target to $28, while Barclays initiated coverage with a lower target of $22. Recent studies also highlighted that responding to MiniMed's diabetes alerts is linked to better glucose outcomes.
Transaction History
| OM | ▲ Buy | Grant | 10,667 | $0 | 6/4/2026 | View on chart |
| MMED | ▲ Buy | Grant | 13,889 | $0 | 3/9/2026 | View on chart |
| OM | ▲ Buy | Grant | 8,983 | $0 | 6/2/2025 | View on chart |
| OM | ▲ Buy | Option Exercise | 187,500 | — | 3/10/2025 | View on chart |
| OM | ▲ Buy | Option Exercise | 31,186 | $35K | 6/3/2024 | View on chart |
| OM | ▼ Sell | Open Market | 26,230 | $100K | 6/3/2024 | View on chart |
| OM | ▲ Buy | Option Exercise | 38,117 | $42K | 6/3/2024 | View on chart |
| OM | ▼ Sell | Open Market | 11,887 | $44K | 6/3/2024 | View on chart |
| OM | ▲ Buy | Grant | 25,000 | $0 | 5/29/2024 | View on chart |
| OM | ▲ Buy | Grant | 7,681 | $0 | 5/31/2023 | View on chart |
| OM | ▲ Buy | Grant | 6,880 | $0 | 5/31/2022 | View on chart |
| OM | ▼ Sell | Open Market | 1,296 | $62K | 12/1/2021 | View on chart |
| OM | ▼ Sell | Open Market | 2,592 | $143K | 11/1/2021 | View on chart |
| OM | ▼ Sell | Open Market | 1,296 | $70K | 11/1/2021 | View on chart |
| OM | ▲ Buy | Option Exercise | 62 | $69 | 10/1/2021 | View on chart |
| OM | ▼ Sell | Open Market | 62 | $3K | 10/1/2021 | View on chart |
| OM | ▼ Sell | Open Market | 1,234 | $61K | 10/1/2021 | View on chart |
| OM | ▲ Buy | Option Exercise | 1,296 | $1K | 9/17/2021 | View on chart |
| OM | ▲ Buy | Option Exercise | 1,296 | $1K | 9/17/2021 | View on chart |
| OM | ▼ Sell | Open Market | 1,296 | $71K | 9/17/2021 | View on chart |
| OM | ▲ Buy | Option Exercise | 1,296 | $1K | 9/17/2021 | View on chart |
| OM | ▼ Sell | Open Market | 1,296 | $71K | 9/17/2021 | View on chart |
| OM | ▼ Sell | Open Market | 1,296 | $71K | 9/17/2021 | View on chart |
| OM | ▼ Sell | Open Market | 1,296 | $71K | 9/17/2021 | View on chart |
| OM | ▲ Buy | Option Exercise | 1,296 | $1K | 9/17/2021 | View on chart |
| OM | ▲ Buy | Option Exercise | 1,296 | $1K | 9/1/2021 | View on chart |
| OM | ▼ Sell | Open Market | 1,296 | $64K | 9/1/2021 | View on chart |
| OM | ▲ Buy | Option Exercise | 1,296 | $1K | 8/26/2021 | View on chart |
| OM | ▼ Sell | Open Market | 1,296 | $58K | 8/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Hims & Hers news mentioned in broader market context
Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.
Hims & Hers news mentioned in broader market context. Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.